Premium
Premium statistics

Industry-specific and extensively researched technical data (partially from exclusive partnerships).

A paid subscription is required for full access.

Public drug program spending in Canada by top 10 drug classes 2017

Top 10 drug classes by total public drug program spending in Canada in 2017 (in million Canadian dollars)*

Public drug program spending in Canada by top 10 drug classes 2017 This statistic displays the total public drug program expenditures in Canada in the top 10 drug classes in 2017. During this year, HMG-CoA reductase inhibitors (statins) which are often used for treating high cholesterol accounted for over 380 million Canadian dollars in public drug expenditures.
Show more

Top 10 drug classes by total public drug program spending in Canada in 2017 (in million Canadian dollars)*

Spending in million Canadian dollars
--
--
--
--
--
--
--
--
--
--
Spending in million Canadian dollars
--
--
--
--
--
--
--
--
--
--
Exclusive Premium statistic

You need a Premium Account for unlimited access.

  • Full access to 1.5m statistics

  • Incl. source references

  • Available to download in PNG, PDF, XLS format

Premium Account

only $49 / month *
*Duration: 12 months, billed annually, single license

Access to this and all other statistics on 80,000 topics from

$588 / Year

Exclusive Premium statistic

You need a Premium Account for unlimited access.

  • Full access to 1.5m statistics

  • Incl. source references

  • Available to download in PNG, PDF, XLS format

Premium Account

only $49 / month *
*Duration: 12 months, billed annually, single license

Access to this and all other statistics on 80,000 topics from

$588 / Year

Download Settings Share
Chart type
Datalabels
Share on Social Media
Download started
Please be patient - this may take a moment

Description

Source

More information

This statistic displays the total public drug program expenditures in Canada in the top 10 drug classes in 2017. During this year, HMG-CoA reductase inhibitors (statins) which are often used for treating high cholesterol accounted for over 380 million Canadian dollars in public drug expenditures.
Show more
Release date
November 2018
Region
Canada
Survey time period
2017
Supplementary notes
* Currently, the Northwest Territories and Nunavut do not submit data to NPDUIS.
** Spending on antivirals for treatment of hepatitis C infections in Prince Edward Island is not included in NPDUIS.
*** Spending on ranibizumab and aflibercept (which accounted for 99.9% of spending on antineovascularization agents) in Nova Scotia, Manitoba and British Columbia, and the majority of this spending in Alberta, is funded through special programs and is not included in NPDUIS.
Statista Accounts: Access All Statistics. Starting from $588 / Year
Basic Account
Get to know the platform

You only have access to basic statistics.
This statistic is not included in your account!

Premium Account
Your perfect start with Statista
  • Instant access to 1m statistics
  • Download in XLS, PDF & PNG format
  • Detailed references

$49 / Month *

Corporate Account
Full access

Corporate solution including all features.

* All products require an annual contract.
   Prices do not include sales tax.
Leading companies trust Statista:
paypalgoogleadobepgsamsungtelekom
Statista is a great source of knowledge, and pretty helpful to manage the daily work.
Christof Baron

Christof Baron
CEO, MindShare Germany

Statistics on "Drug use in the Nordic countries"
  • Cannabis
The most important statistics
  • Amphetamines, cocoaine, ecstasy
  • Tobacco
  • Prices
  • Drug treatments
  • Deaths and crime
  • Seizures
Need help with using Statista for your research? Tutorials and first steps
Further Content: Statistics, Studies, and Topic Pages
Learn more about how Statista can support your business.
Do you have any questions about our business solutions?

We provide you with detailed information about our Corporate Account.